Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch, Focus On Acquisitions: Emergent Acquires PaxVax, Pair Of Commercialized Vaccines

Executive Summary

Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.

Advertisement

Related Content

Glenmark Spins Out Business To Drive Value
Bye Bye Vernalis And Another Blow For UK Biotech
Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?
Perrigo's OTC Core Could Expand To Include National Brands
Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio
Zydus Partners Medicure To Launch First Branded Drug In US
Millendo Gets European Foothold With Alizé Acquisition
Takeda-Zydus Enter Increasingly Crowded Chikungunya Fray
Millendo Raises $62m, Licenses AstraZeneca Drug
Aralez Pharma, Anchored In Cardiovascular, Will Be Prowling For Assets

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123694

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel